Shunwei & Morningside Return to Neuro Drug Developer
29 Sep 2026
US$ 20.00
Shunwei Capital and Morningside Ventures were among the returning investors in the over US$50 m series A funding round...
Related Publications
South Korea is expanding the role of its sovereign wealth fund (SWF) as the government seeks to mobilise long-term...
Despite its long history in the private equity/venture capital industry, a foreign-sponsored dedicated Japan private...
Connect With Us
We love to share Asia PE insights and news from time to time. Drop us your email address if you like to hear from us.
Rest assured that your email address will not be shared, as we hate spams as much as you do.